To identify whether TACC3 is an immunosuppressive factor in vivo, tumor models were constructed using PLC/PRF/5 and Hepa1‒6 cell lines in which TACC3 was knocked out via CRISPR/Cas9 technology, as validated by western blotting analysis (Supplementary Fig. 3a, b). Here, TACC3 is linked to neoplasm.